Monte Rosa Therapeutics, Inc.
Industry
- Pharmaceuticals
- Vaccines
- Biotechnology
- Drug Discovery Technologies
- ADMET
- Molecular Diversity
- Drug Discovery Technologies
Latest on Monte Rosa Therapeutics, Inc.
Degron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas. MGDs, an emerging dru
Who: Roche’s Genentech/Orionis Biosciences What: The companies signed a second deal focused on molecular glue drugs in oncology. Why: The deal expands on an existing partnership between Orionis
AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months
Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth